Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (relapsed/refractory) | Do not reimburse | Complete | ||
Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (first-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Treanda | Bendamustine hydrochloride | Non-Hodgkin Lymphoma and Mantle Cell Lymphoma | Reimburse | Complete | ||
Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Orladeyo | berotralstat | hereditary angioedema (HAE) | Reimburse with clinical criteria and/or conditions | Complete | ||
Mvasi | Bevacizumab | mCRC NSCLC Biosimilar | N/A | Complete | ||
TBD | Bevacizumab | Cancelled | ||||
Avastin | Bevacizumab | Platinum Resistant Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Avastin (with capecitabine) | Bevacizumab | Metastatic Colorectal Cancer | Reimburse with clinical criteria and/or conditions | Complete |